FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an immunoconjugate that binds to CD79b, a pharmaceutical composition for treating a subject suffering from a cancerous B-cell proliferative disorder, the use of an effective amount of an immunoconjugate or a pharmaceutical composition for the manufacture of a medicament for the treatment of an individual suffering from a malignant B-cell proliferative disorder, and a method for the preparation of the immunoconjugate. In one implementation, the immunoconjugate contains an anti-CD79b antibody containing a heavy chain variable domain containing the SEQ ID NO: 208 sequence and a light chain variable domain containing the SEQ ID NO: 207 sequence.
EFFECT: expansion of the arsenal of agents specifically binding to CD79b.
45 cl, 71 dwg, 20 tab, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817143C2 |
| COMPOSITIONS OF ANTIBODIES AGAINST ROR1 AND CORRESPONDING METHODS | 2017 |
|
RU2766190C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| METHOD OF PURIFICATION FOR REMOVING TYROSINE SULPHATED ANTIBODIES VARIANTS, PURIFIED COMPOSITIONS | 2017 |
|
RU2793400C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| ANTI-IDIOTYPIC ANTIBODIES AND METHODS RELATED TO THEM | 2017 |
|
RU2773355C2 |
| 5-BROMO-2,6-DI - (1H-PYRAZOL-1-YL)PYRIMIDINE-4-AMINE FOR USE IN CANCER TREATMENT | 2016 |
|
RU2745560C2 |
| METHODS FOR USING CD32B x CD79B-BINDING MOLECULES IN TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | 2017 |
|
RU2772434C2 |
